Loading…
This event has ended. Visit the official site or create your own event on Sched.
avatar for Matt Likens

Matt Likens

GT Medical Technologies
CEO
After graduating cum laude from Kent State University with a bachelor’s of business administration degree and a major in marketing, Mr. Likens began his professional career with Johnson & Johnson Corporation. He then spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the position of President, Baxter Biotech North America, followed by President of Baxter’s Renal Division in the U.S.

In July of 2006, Mr. Likens became President and CEO and the second employee of Ulthera, Inc., a venture capital-backed start-up company in energy-based aesthetics in Phoenix, AZ. Beginning with European regulatory clearance in late 2008, followed by FDA clearance in September of 2009, Ulthera realized net revenue growth from $0.5M in ’08 to over $117M in 2014. After filing for an IPO in early 2014, Ulthera attracted interest from several larger companies, and in July of that year, was acquired by Merz Pharma GmbH for $600M, an amount representing 6.6x trailing 12-months’ revenue. The Arizona Association for Corporate Growth (ACG) recognized this as Transaction of the Year for 2014.

Phoenix Business Journal honored Mr. Likens in 2012, naming him one of Arizona’s Most Admired CEOs.

In June of 2015, Ernst & Young named Mr. Likens Entrepreneur of the Year for the Mountain Desert Region, which recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.

Matt is currently the CEO of GT Medical Technologies here in the valley. There he is working with a founding group of five physicians from The Barrow Neurological Institute in Phoenix, who developed GammaTile, which is an implantable radiation device that is used to treat patients with brain tumors. Our purpose is “Improving the lives of patients with brain tumors”. He is also a board member for privately-held Luma Therapeutics and NASDAQ-listed CHF Solutions, as well as being a venture partner at MedTech Venture Partners in Mission Bay, CA.